CheckMate 9DW: Ipi/Nivo as First-Line Treatment for uHCC

Peter R. Galle, MD, PhD, of University Medical Center Mainz, shares the first results from CheckMate 9DW, a comparison of nivolumab plus ipilimumab against sorafenib or lenvatinib as first-line treatments for unresectable HCC.

He expands on what the long-term survival data suggests about the effectiveness of this combination therapy in this population.